JP2005510246A5 - - Google Patents

Download PDF

Info

Publication number
JP2005510246A5
JP2005510246A5 JP2003547635A JP2003547635A JP2005510246A5 JP 2005510246 A5 JP2005510246 A5 JP 2005510246A5 JP 2003547635 A JP2003547635 A JP 2003547635A JP 2003547635 A JP2003547635 A JP 2003547635A JP 2005510246 A5 JP2005510246 A5 JP 2005510246A5
Authority
JP
Japan
Prior art keywords
seq
referred
heavy chain
antibody
functional fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003547635A
Other languages
English (en)
Japanese (ja)
Other versions
JP4519464B2 (ja
JP2005510246A (ja
Filing date
Publication date
Priority claimed from US09/995,529 external-priority patent/US7365167B2/en
Priority claimed from US10/011,250 external-priority patent/US7390885B2/en
Application filed filed Critical
Publication of JP2005510246A publication Critical patent/JP2005510246A/ja
Publication of JP2005510246A5 publication Critical patent/JP2005510246A5/ja
Application granted granted Critical
Publication of JP4519464B2 publication Critical patent/JP4519464B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003547635A 2001-11-26 2002-11-26 ヒト化コラーゲン抗体および関連方法 Expired - Fee Related JP4519464B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/995,529 US7365167B2 (en) 2001-11-26 2001-11-26 Humanized collagen antibodies and related methods
US10/011,250 US7390885B2 (en) 2001-11-26 2001-12-06 Humanized collagen antibodies and related methods
PCT/US2002/038147 WO2003046204A2 (en) 2001-11-26 2002-11-26 Humanized collagen antibodies and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009167279A Division JP2009240324A (ja) 2001-11-26 2009-07-15 ヒト化コラーゲン抗体および関連方法

Publications (3)

Publication Number Publication Date
JP2005510246A JP2005510246A (ja) 2005-04-21
JP2005510246A5 true JP2005510246A5 (https=) 2006-01-12
JP4519464B2 JP4519464B2 (ja) 2010-08-04

Family

ID=26682164

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003547635A Expired - Fee Related JP4519464B2 (ja) 2001-11-26 2002-11-26 ヒト化コラーゲン抗体および関連方法
JP2009167279A Withdrawn JP2009240324A (ja) 2001-11-26 2009-07-15 ヒト化コラーゲン抗体および関連方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009167279A Withdrawn JP2009240324A (ja) 2001-11-26 2009-07-15 ヒト化コラーゲン抗体および関連方法

Country Status (11)

Country Link
US (4) US7390885B2 (https=)
EP (1) EP1478764B1 (https=)
JP (2) JP4519464B2 (https=)
CN (1) CN1596313B (https=)
AT (1) ATE509955T1 (https=)
AU (1) AU2009200070A1 (https=)
CA (1) CA2468016A1 (https=)
IL (1) IL162117A0 (https=)
MX (1) MXPA04004857A (https=)
NZ (1) NZ533408A (https=)
WO (1) WO2003046204A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
EP2054442A2 (en) * 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denatured collagen peptides and uses thereof
MX2008015830A (es) * 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
WO2008081008A1 (en) * 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20110287036A1 (en) * 2008-11-17 2011-11-24 Riken Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
EP2770327B1 (en) * 2009-03-30 2017-06-14 Nordic Bioscience A/S Fibrosis biomarker assay
CA2773356A1 (en) 2009-10-20 2011-04-28 Maine Medical Center Compositions and methods for treating inflammation and fibrosis
EP2544694B1 (en) * 2010-03-02 2018-10-31 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
WO2012063839A1 (ja) * 2010-11-10 2012-05-18 日本化薬株式会社 抗1本鎖iv型コラーゲンポリペプチド抗体、並びに該抗体を含む医薬、及び腫瘍の診断薬、予防薬、又は治療薬
BR112014006394A2 (pt) * 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
USRE49477E1 (en) 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
CA2887050A1 (en) 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
US9725520B2 (en) 2013-03-14 2017-08-08 The Board Of Regents Of The University Of Texas System HER3 specific monoclonal antibodies for diagnostic and therapeutic use
DK3515478T3 (da) * 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
EP3775258A4 (en) 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
CN113507935A (zh) * 2018-10-16 2021-10-15 得克萨斯州大学系统董事会 用于诊断和治疗癌症及其他疾病的对致病性胞外基质的鉴定和靶向
WO2020102779A1 (en) * 2018-11-16 2020-05-22 Albert Einstein College Of Medicine MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
CN113286823B (zh) * 2019-01-28 2024-05-07 上海拓界生物医药科技有限公司 抗cd79b抗体、其抗原结合片段及其医药用途
WO2021252974A2 (en) * 2020-06-11 2021-12-16 Proviva Therapeutics (Hong Kong) Limited Collagen-targeted fusion proteins and antibodies
WO2022147298A1 (en) * 2020-12-31 2022-07-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Vascular-endothelial cadherin activating antibodies and uses thereof
US20240358850A1 (en) * 2023-04-13 2024-10-31 MaineHealth Compositions and methods for an antibody drug conjugate directed to a non-cell surface therapeutic target

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US91482A (en) * 1869-06-15 Improvement in harvesters
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
EP0184365B1 (en) * 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5871974A (en) 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
JP3105629B2 (ja) 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
DK0528767T3 (da) 1991-08-21 2000-04-17 Novartis Ag antistofderivater
DE4127790A1 (de) 1991-08-22 1993-02-25 Wank Anna Verwendung von oligopeptiden mit 2 bis 5 peptidbindungen fuer kosmetische zwecke und einige neue oligopeptid-metallkomplexe
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH0675216A (ja) 1992-08-27 1994-03-18 Hitachi Ltd 液晶表示装置
US6132976A (en) * 1992-12-04 2000-10-17 Shriners Hospitals For Children Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
CA2148132A1 (en) 1992-12-04 1994-06-23 Anthony Robin Poole Immunoassay for the measurement of collagen cleavage in cartilage
US5541295A (en) * 1993-02-12 1996-07-30 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Detection of type II collagen and its peptides
FI960392A7 (fi) 1993-07-28 1996-01-29 Roche Diagnostics Gmbh Immunomääritys kollageenin tai kollageenifragmenttien osoittamiseksi
US5510391A (en) 1993-10-22 1996-04-23 Mayapple Holdings, Llc Method of treating blood vessel disorders of the skin using vitamin K
US5465826A (en) * 1994-02-24 1995-11-14 Valiant Machine & Tool, Inc. Conveyor system
US5560910A (en) 1994-08-26 1996-10-01 Crandall; Wilson T. Topical anti-inflammatory composition and method
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5763272A (en) * 1994-12-23 1998-06-09 Boehringer Mannheim Gmbh Hybridoma for producing antibody for collagen I
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5756775A (en) * 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
WO1997039746A1 (en) 1996-04-22 1997-10-30 Advanced Polymer Systems, Inc. Method of and composition for treating disorders of the skin using vitamin k
WO1997044059A2 (en) 1996-05-23 1997-11-27 Shriner's Hospitals For Children Cartilage type ii collagen as an angiogenic factor
US6492508B1 (en) 1996-06-03 2002-12-10 United States Surgical Corp. A Division Of Tyco Healthcare Group Nucleic acids encoding extracellular matrix proteins
WO1999011208A1 (en) 1997-08-28 1999-03-11 Williams C Donald Method and composition for transdermal administration of pharmacologic agents
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
GB9702252D0 (en) 1997-02-06 1997-03-26 Univ Sheffield Medical The Sch Collagen assay
US5817699A (en) * 1997-05-30 1998-10-06 Flores; John A. Process for the preparation of ketamine ointment
ES2214722T3 (es) 1997-07-31 2004-09-16 Metra Biosystems, Inc. Metodo de ensayo de peptidos de colageno.
WO1999006834A2 (en) 1997-08-04 1999-02-11 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
US6030792A (en) 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
ES2246093T3 (es) 1998-10-16 2006-02-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Patogenicida molecular que induce una resistencia a la enfermedad en las plantas.
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
ES2333845T3 (es) 1999-01-06 2010-03-02 University Of Southern California Metodo y composicion para la inhibicion de la angiogenesis.
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
CA2379373A1 (en) 1999-07-13 2001-01-18 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins
AU760486B2 (en) 1999-10-13 2003-05-15 Incyte Genomics, Inc. Multiplex cytokine analysis
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP4398620B2 (ja) 2000-02-03 2010-01-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ccr−2抗体およびその使用方法
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
US6696254B2 (en) 2001-11-21 2004-02-24 Kimberly-Clark Worldwide, Inc. Detection and identification of enteric bacteria
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
WO2005017485A2 (en) 2003-05-22 2005-02-24 Agdia, Inc. Multiplex enzyme-linked immunosorbent assay for detecting multiple analytes
JP2005347062A (ja) 2004-06-02 2005-12-15 Hitachi Displays Ltd バックライト装置及び液晶表示装置
JP2006075216A (ja) 2004-09-07 2006-03-23 Toshiba Corp 医用画像処理システム、医用画像処理プログラムおよび医用画像処理方法
EP2054442A2 (en) 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denatured collagen peptides and uses thereof

Similar Documents

Publication Publication Date Title
JP2005510246A5 (https=)
JP2024167313A5 (https=)
JP2025111463A5 (https=)
JP2022031635A5 (https=)
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2011509245A5 (https=)
HRP20181069T1 (hr) Antagonistička protutijela na il-17
ME02581B (me) Farmaceutski pripravci s otpornošću na topljivi cea
JP2009225799A5 (https=)
JP2005503789A5 (https=)
JP2004527212A5 (https=)
JP2010502183A5 (https=)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2010533498A5 (https=)
JP2010536384A5 (https=)
JP2008532949A5 (https=)
JP2022512234A5 (https=)
JP2010511388A5 (https=)
JP2021521781A5 (https=)
WO2002072832A3 (en) Therapeutic binding molecules
JP2008538292A5 (https=)
JP2012500020A5 (https=)
JP2018537421A5 (https=)
JP2007530551A5 (https=)
JP2010524435A5 (https=)